Do neurologists in Germany adhere to the national Parkinson's disease guideline? (original) (raw)

Parkinson's disease severity and use of dopaminergic medications

Parkinsonism & Related Disorders, 2015

A reassessment of risks and benefits of dopamine agonists in Parkinson's disease

The Lancet Neurology, 2009

Tolerability of non-ergot oral and transdermal dopamine agonists in younger and older Parkinson’s disease patients: an European multicentre survey

A. Rizos

Journal of Neural Transmission, 2020

View PDFchevron_right

gUIDELINE COMPARISON AND ASSESSMENT OF PRESCRIbINg TRENDS IN PARKINSON’S DISEASE

Marise Gauci

2019

View PDFchevron_right

Sydney multicenter study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years

Wayne Reid

Movement Disorders, 2005

View PDFchevron_right

DOPA-sparing strategy in the treatment of young onset Parkinson's disease

Syed Fasih Ullah Hussaini

Journal of Neurosciences in Rural Practice, 2016

View PDFchevron_right

The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study

Clelia Pellicano

European journal of medical research, 2013

View PDFchevron_right

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review

Edna Schechtman

Neurology

View PDFchevron_right

Patterns and Determinants of Prescribing for Parkinson’s Disease: A Systematic Literature Review

Khalid Orayj

Parkinson's Disease, 2019

View PDFchevron_right

Correlation Between the Age, Motor Subtypes and the Necessity of Advanced Therapy in Parkinson Disease

Diana Stanca

Revista de Chimie

View PDFchevron_right

The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson’s Disease: A Feasibility Study

Bethany Snyder

Journal of Parkinson's Disease, 2020

View PDFchevron_right

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society?European Section. Part I: early (uncomplicated) Parkinson's disease

Cristina Sampaio

European Journal of Neurology, 2006

View PDFchevron_right

Motor and non-motor symptoms of 1453 patients with Parkinson's disease: Prevalence and risks

Taku Hatano

Parkinsonism & Related Disorders, 2013

View PDFchevron_right

Treatment of Parkinson's disease should begin with a dopamine agonist

Olivier Rascol

Movement Disorders, 2000

View PDFchevron_right

Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson’s Disease: A Prospective, Cross-Sectional Study in Non-demented Patients

Jaime Kulisevsky

Drugs & Aging, 2015

View PDFchevron_right

No Sex Differences in Use of Dopaminergic Medication in Early Parkinson Disease in the US and Canada - Baseline Findings of a Multicenter Trial

Oksana Suchowersky, Chadwick Christine, Adriana Pérez, Anne-marie Wills

PLoS ONE, 2014

View PDFchevron_right

European Physiotherapy Guideline for Parkinson's Disease Developed with twenty European professional associations

Katherine Bruce

View PDFchevron_right

Parkinson’s disease between internal medicine and neurology

Ilona Csóti

Journal of Neural Transmission, 2015

View PDFchevron_right

Agonistas dopaminérgicos en la enfermedad de Parkinson

R. Piudo, J. Del Val, G. Linazasoro

Neurología, 2014

View PDFchevron_right

Treatments for progressing Parkinson's disease: a clinical case scenario study

Patrick Santens

Acta neurologica Belgica

View PDFchevron_right

Characterization of advanced Parkinson’s disease in Germany: results of the non-interventional OBSERVE-PD study

Wolfgang Jost

Neurological Research and Practice

View PDFchevron_right

Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial

Emma McIntosh

Lancet, 2014

View PDFchevron_right

Standard strategies for diagnosis and treatment of patients with newly diagnosed Parkinson disease

Francisco Cardoso

Neurology: Clinical Practice, 2013

View PDFchevron_right

Should Dopamine Agonists be Given Early or Late in the Treatment of Parkinson’s Disease?

abraham lieberman

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 1984

View PDFchevron_right

Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson’s disease: a systematic review

Guy Camp

Journal of Neural Transmission, 2009

View PDFchevron_right

Diagnosis and Pharmacological Management of Parkinson's Disease: A Review

International Journal of Health Sciences and Research (IJHSR)

https://www.ijhsr.org/IJHSR\_Vol.12\_Issue.2\_Feb2022/IJHSR-Abstract.015.html, 2022

View PDFchevron_right

Pharmacokinetic Optimisation of Dopamine Receptor Agonist Therapy for Parkinson??s Disease

Manuela Contin

CNS Drugs, 2000

View PDFchevron_right

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease

Olivier Rascol

European Journal of Neurology, 2006

View PDFchevron_right

Age-standardized incidence and prevalence of Parkinson's disease in a Swedish community

Björn Lindvall

Journal of Clinical Epidemiology, 1996

View PDFchevron_right

Guidelines for the Diagnosis and Treatment of Parkinson’s Disease

James Brasic

ECCM 2021, 2021

View PDFchevron_right

Do neurologists in Germany adhere to the national Parkinson's disease guideline? (original) (raw)

Related papers